Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer - Test2 - elhamkhani - TriplyDB

Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer

Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer

http://www.wikidata.org/entity/Q24654216

about

Identification of primary gene targets of TFAP2C in hormone responsive breast carcinoma cells Conditional Wwox deletion in mouse mammary gland by means of two Cre recombinase approaches.WWOX suppresses KLF5 expression and breast cancer cell growth WWOX expression in colorectal cancer--a real-time quantitative RT-PCR study.The cancer gene WWOX behaves as an inhibitor of SMAD3 transcriptional activity via direct binding Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options.Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition.Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features Regulation of cell signaling and apoptosis by tumor suppressor WWOX.Roles of the WWOX in pathogenesis and endocrine therapy of breast cancer.Adjuvant therapy of triple negative breast cancer.WWOX gene and gene product: tumor suppression through specific protein interactions.WWOX: a fragile tumor suppressor.Pc2-mediated SUMOylation of WWOX is essential for its suppression of DU145 prostate tumorigenesis.Association of downregulation of WWOX with poor prognosis in patients with intrahepatic cholangiocarcinoma after curative resection.Wwox inactivation enhances mammary tumorigenesis.Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.Immunohistochemical expression of epidermal growth factor receptor in breast cancer.Tumor Suppressor Gene in Breast Cancer, a Historical Perspective and Future Directions Loss of Wwox drives metastasis in triple-negative breast cancer by JAK2/STAT3 axis Somatic loss of WWOX is associated with TP53 perturbation in basal-like breast cancer

P2860

Q24626014-A5D15DE2-DC1D-4B92-95C6-88E406BCCC73 Q34264825-15C2FEB4-BF22-4D7A-8EDC-C7312EC59A3F Q34452812-4AFB0E02-A5F0-4B82-BF88-CF5C11573A1E Q34978090-A567A38C-F148-4B28-A092-29DE59678EAC Q35065263-6E463442-8522-4164-AEE8-8113FC4F0D24 Q35088745-D2D31E76-B87E-4DA6-A6D8-AD5883DE1089 Q35353424-827B7B41-EBA2-4D94-A6AA-B53D146820D2 Q36914825-CDDEBE42-54BC-4516-A98D-4B25B00951F6 Q37071049-3972473B-283B-4D7A-B032-06DEE44ECD73 Q37071054-7D7DD2B9-B1E1-434A-8527-98A4DDDC5E39 Q37571648-40AD9A6B-5B8B-4843-9C87-E1DB8A84B596 Q37690302-5EBE2E5A-5080-43DB-BB16-F3ED869B562F Q38299692-FF5B7682-98EF-4C47-A6E6-7D32E41B237A Q38817885-D3BB8EAC-F4B9-4A90-B5CA-6CBC23D2C87D Q38962085-C58FC14C-D6FD-4FBE-B8C2-7BFB525F31B7 Q39557407-614A7F18-7404-4336-A7F9-E4F55A464F2B Q50753687-9C00CAFC-86E8-4D5C-8DDE-E56B961D8A77 Q54688681-66F27978-DCE5-4924-B19B-3B13782135A2 Q57107482-FC8147C5-7798-4749-858B-AFF79F427DAD Q58699452-17BF81F6-8152-422A-B080-8EF2AAF56F71 Q58799648-266A53ED-7F34-4A26-8DC6-602D6B72914F

P2860

Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer

http://www.wikidata.org/entity/Q24654216

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Fragile histidine triad protei ...... sal phenotype in breast cancer

@ast

Fragile histidine triad protei ...... sal phenotype in breast cancer

@en

Fragile histidine triad protei ...... sal phenotype in breast cancer

@nl

type

label

Fragile histidine triad protei ...... sal phenotype in breast cancer

@ast

Fragile histidine triad protei ...... sal phenotype in breast cancer

@en

Fragile histidine triad protei ...... sal phenotype in breast cancer

@nl

prefLabel

Fragile histidine triad protei ...... sal phenotype in breast cancer

@ast

Fragile histidine triad protei ...... sal phenotype in breast cancer

@en

Fragile histidine triad protei ...... sal phenotype in breast cancer

@nl

P1433

Q24654216-A59AC03E-1F6E-4767-899F-FDA644E31862

P1476

Q24654216-94DD5914-FCCF-4D16-9405-3A1DC7386E04

P2093

Q24654216-36F3E8F5-A628-4B95-9EDA-5ABB6FB59421

Q24654216-80E304CD-21BD-458B-AC98-A9BFCD1D555E

Q24654216-9B80BFCF-B87D-4E45-BFEC-E8AB326F5C47

Q24654216-9D530B7F-609B-4378-9AC0-FC554DD2352F

Q24654216-A0AEFBB7-DC6C-4045-9500-3E01DA013CAE

Q24654216-B45790D5-0F1A-4126-9316-FA5A066942B9

Q24654216-BAECCC5E-E9FD-45FF-97CB-2B6774B857F1

Q24654216-EBFAF4FC-638F-48F4-845F-27470D47F622

P2860

Q24654216-0559474D-BFB1-4D78-9614-5323800EC08A

Q24654216-06F7D447-8225-42B5-AB69-EC64DFDB5A70

Q24654216-08EFBE97-213F-444C-AC54-47C983A11597

Q24654216-0DF05318-BD29-4706-9FA6-A6EC1FFC2A84

Q24654216-17C339F6-93A0-4BC1-A3E4-711783194CF6

Q24654216-1D310BD9-4B61-482B-A0D2-6EF9323104DE

Q24654216-2189ECB5-3444-4CCE-B6BB-D7AF1EF2B0EF

Q24654216-24368839-EB28-4309-9FF9-DBC2874B00C0

Q24654216-24AD6426-9A5D-4061-BC94-21CB063BBA45

Q24654216-2534B211-4F5C-4164-B6DC-5B8682EC610A

P304

Q24654216-692B47BB-EFFB-4A3C-BBE8-8D6E87B78C74

P31

Q24654216-DE0F071C-8983-4D64-B37F-D089CDEDD7E2

P356

Q24654216-44CB43A5-FBB1-4133-8F39-6F12EF7EE750

P407

Q24654216-CD6FBEFA-B6AD-4507-85C2-6278E84EB071

P433

Q24654216-22CD43C4-0602-43EF-8AB5-2E0B21547321

P478

Q24654216-AF30FA98-E557-4E11-8B9F-33868628E878

P50

Q24654216-69002909-729D-4A6E-97E4-FF47D7CFCD7D

P577

Q24654216-7C4957FA-36E0-4107-A0AB-F892E5C81261

P5875

Q24654216-3F83D3A3-6ED8-4CA1-B615-A60484B0C786

P698

Q24654216-746896E7-A1F5-4A8E-A26D-C973BB9897ED

P932

Q24654216-CC9FD7C8-78B0-42C6-8260-C233A0FBDDB9

P356

P1433

P1476

Fragile histidine triad protei ...... sal phenotype in breast cancer

@en

P2093

Charles L Shapiro

http://www.w3.org/2001/XMLSchema#string

Cigdem Himmetoglu

http://www.w3.org/2001/XMLSchema#string

Gulnur Guler

http://www.w3.org/2001/XMLSchema#string

Kay Huebner

http://www.w3.org/2001/XMLSchema#string

Mutlu Hayran

http://www.w3.org/2001/XMLSchema#string

Rafael E Jimenez

http://www.w3.org/2001/XMLSchema#string

Robert T Pilarski

http://www.w3.org/2001/XMLSchema#string

Stefan Costinean

http://www.w3.org/2001/XMLSchema#string

P2860

WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function

The tumor spectrum in FHIT-deficient mice

Muir-Torre-like syndrome in Fhit-deficient mice

Targeted deletion of Wwox reveals a tumor suppressor function

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Molecular portraits of human breast tumours

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma

Targeted cancer therapies based on the inhibition of DNA strand break repair

P304

899-908

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.24103

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

Stefano Volinia

P577

2009-02-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23765255

http://www.w3.org/2001/XMLSchema#string

P698

19130459

http://www.w3.org/2001/XMLSchema#string

P932

2640223

http://www.w3.org/2001/XMLSchema#string